The myofibroblast matrix: Implications for tissue repair andfibrosis

Journal of Pathology

Volumn 229, Issue 2, 2013, Pages 298-309

  Klingberg, Franco ^a   Hinz, Boris ^a   White, Eric S ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ECM; fibrosis; myofibroblast

Indexed keywords

COLLAGEN; COLLAGEN TYPE 3; COLLAGEN TYPE 5; COLLAGEN TYPE 6; CONNECTIVE TISSUE GROWTH FACTOR; ELASTIN; FIBRILLIN; FIBRONECTIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; PROTEOGLYCAN; TENASCIN;

BLEEDING; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; FIBROSIS; HUMAN; MORBIDITY; MORTALITY; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; TISSUE REPAIR; WOUND HEALING;

ANIMALS; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; HOMEOSTASIS; HUMANS; MYOFIBROBLASTS; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 84871046283     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4104     Document Type: Review

References (232)

1. Hinz B, Phan SH, Thannickal VJ, et al,. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012; 180: 1340-1355.
2. Wynn TA,. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210. (Pubitemid 351160157)
3. Hinz B,. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007; 127: 526-537.
4. Hardie WD, Glasser SW, Hagood JS,. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol 2009; 175: 3-16.
5. Araya J, Nishimura SL,. Fibrogenic reactions in lung disease. Annu Rev Pathol 2010; 5: 77-98.
6. Wynn TA,. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208: 1339-1350.
7. Hernandez-Gea V, Friedman SL,. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456.
8. Iredale J,. Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol Res 2008; 58: 129-136.
9. Iwaisako K, Brenner DA, Kisseleva T,. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol 2012; 27 (Suppl 2): 65-68.
10. Meran S, Steadman R,. Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Pathol 2011; 92: 158-167.
11. Grande MT, Lopez-Novoa JM,. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nature Rev Nephrol 2009; 5: 319-328.
12. Serrano AL, Mann CJ, Vidal B, et al,. Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Curr Top Dev Biol 2011; 96: 167-201.
13. Beyer C, Distler O, Distler JH,. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012; 24: 274-280.
14. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-567. (Pubitemid 46348510)
15. Asano Y,. Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
16. van den Borne SW, Diez J, Blankesteijn WM, et al,. Myocardial remodeling after infarction: the role of myofibroblasts. Nature Rev Cardiol 2010; 7: 30-37.
17. Rohr S,. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias? Heart Rhythm 2009; 6: 848-856.
18. Krenning G, Zeisberg EM, Kalluri R,. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 2010; 225: 631-637.
19. De Wever O, Demetter P, Mareel M, et al,. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123: 2229-2238.
20. Otranto M, Sarrazy V, Bonte F, et al,. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr 2012; 6: 203-219.
21. Hinz B, Phan SH, Thannickal VJ, et al,. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807-1816. (Pubitemid 47339255)
22. Dranoff JA, Wells RG,. Portal fibroblasts: underappreciated mediators of biliary fibrosis. Hepatology 2010; 51: 1438-1444.
23. Desmoulière A,. Hepatic stellate cells: the only cells involved in liver fibrogenesis? A dogma challenged. Gastroenterology 2007; 132: 2059-2062. (Pubitemid 46677959)
24. Cirri P, Chiarugi P,. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 2012; 31: 195-208.
25. Porter KE, Turner NA,. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009; 123: 255-278.
26. Herzog EL, Bucala R,. Fibrocytes in health and disease. Exp Hematol 2010; 38: 548-556.
27. Keeley EC, Mehrad B, Strieter RM,. The role of fibrocytes in fibrotic diseases of the lungs and heart. Fibrogenesis Tissue Repair 2011; 4: 2.
28. Bellini A, Mattoli S,. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007; 87: 858-870. (Pubitemid 47267815)
29. Coen M, Gabbiani G, Bochaton-Piallat ML,. Myofibroblast-mediated adventitial remodeling: an underestimated player in arterial pathology. Arterioscler Thromb Vasc Biol 2011; 31: 2391-2396.
30. Humphreys BD, Lin SL, Kobayashi A, et al,. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
31. Lin SL, Kisseleva T, Brenner DA, et al,. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008; 173: 1617-1627.
32. Armulik A, Genove G, Betsholtz C,. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011; 21: 193-215.
33. Kidd S, Spaeth E, Watson K, et al,. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One 2012; 7: e30563.
34. Chapman HA,. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol 2011; 73: 413-435.
35. Burns WC, Thomas MC,. The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology. Expert Rev Mol Med 2010; 12: e17.
36. Quaggin SE, Kapus A,. Scar wars: mapping the fate of epithelial- mesenchymal-myofibroblast transition. Kidney Int 2011; 80: 41-50.
37. Lee K, Nelson CM,. New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. Int Rev Cell Mol Biol 2012; 294: 171-221.
38. Piera-Velazquez S, Li Z, Jimenez SA,. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 2011; 179: 1074-1080.
39. Mishra PJ, Glod JW, Banerjee D,. Mesenchymal stem cells: flip side of the coin. Cancer Res 2009; 69: 1255-1258.
40. Hinz B., The myofibroblast in connective tissue repair and regeneration. In Regenerative Medicine and Biomaterials for the Repair of Connective Tissues, Archer C, Ralphs J, (eds). Woodhead Publishing Ltd: Cambridge, 2010; 39-82.
41. Kis K, Liu X, Hagood JS,. Myofibroblast differentiation and survival in fibrotic disease. Expert Rev Mol Med 2011; 13: e27.
42. Sandbo N, Dulin N,. Actin cytoskeleton in myofibroblast differentiation: ultrastructure defining form and driving function. Transl Res 2011; 158: 181-196.
43. Follonier Castella L, Gabbiani G, McCulloch CA, et al,. Regulation of myofibroblast activities: calcium pulls some strings behind the scene. Exp Cell Res 2010; 316: 2390-2401.
44. Hinz B, Gabbiani G,. Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives. F1000 Biol Rep 2010; 2: 78.
45. Douglass A, Wallace K, Koruth M, et al,. Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. Hepatol Int 2008; 2: 405-415.
46. Sivakumar P, Ntolios P, Jenkins G, et al,. Into the matrix: targeting fibroblasts in pulmonary fibrosis. Curr Opin Pulm Med 2012; 18: 462-469.
47. Leask A,. Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment. Fibrogenesis Tissue Repair 2010; 3: 8.
48. Scotton CJ, Chambers RC,. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007; 132: 1311-1321. (Pubitemid 47621009)
49. Frantz C, Stewart KM, Weaver VM,. The extracellular matrix at a glance. J Cell Sci 2010; 123: 4195-4200.
50. Hynes RO,. The evolution of metazoan extracellular matrix. J Cell Biol 2012; 196: 671-679.
51. Ozbek S, Balasubramanian PG, Chiquet-Ehrismann R, et al,. The evolution of extracellular matrix. Mol Biol Cell 2010; 21: 4300-4305.
52. Schultz GS, Wysocki A,. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009; 17: 153-162.
53. Discher DE, Mooney DJ, Zandstra PW,. Growth factors, matrices, and forces combine and control stem cells. Science 2009; 324: 1673-1677.
54. Macri L, Silverstein D, Clark RA,. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 2007; 59: 1366-1381. (Pubitemid 350090013)
55. Gabbiani G, Ryan GB, Majno G,. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971; 27: 549-550.
56. Tomasek JJ, Gabbiani G, Hinz B, et al,. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature Rev Mol Cell Biol 2002; 3: 349-363. (Pubitemid 34619269)
57. Hinz B,. The myofibroblast: paradigm for a mechanically active cell. J Biomech 2010; 43: 146-155.
58. Cukierman E, Pankov R, Stevens DR, et al,. Taking cell-matrix adhesions to the third dimension. Science 2001; 294: 1708-1712. (Pubitemid 33104840)
59. Rohr S,. Cardiac fibroblasts in cell culture systems: myofibroblasts all along? J Cardiovasc Pharmacol 2011; 57: 389-399.
60. Zhang K, Rekhter MD, Gordon D, et al,. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol 1994; 145: 114-125. (Pubitemid 24217490)
61. Tomasek JJ, Schultz RJ, Episalla CW, et al,. The cytoskeleton and extracellular matrix of the Dupuytren's disease myofibroblast': an immunofluorescence study of a nonmuscle cell type. J Hand Surg Am 1986; 11: 365-371. (Pubitemid 16121393)
62. Chang LY, Overby LH, Brody AR, et al,. Progressive lung cell reactions and extracellular matrix production after a brief exposure to asbestos. Am J Pathol 1988; 131: 156-170.
63. Kuhn C, McDonald JA,. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991; 138: 1257-1265.
64. Berndt A, Kosmehl H, Katenkamp D, et al,. Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology 1994; 62: 55-58. (Pubitemid 24215140)
65. Aigner T, Neureiter D, Muller S, et al,. Extracellular matrix composition and gene expression in collagenous colitis. Gastroenterology 1997; 113: 136-143. (Pubitemid 27281767)
66. Magro G, Fraggetta F, Colombatti A, et al,. Myofibroblasts and extracellular matrix glycoproteins in palmar fibromatosis. Gen Diagn Pathol 1997; 142: 185-190. (Pubitemid 27104368)
67. Mahida YR, Beltinger J, Makh S, et al,. Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am J Physiol 1997; 273: G1341 - G1348.
68. Stokes MB, Hudkins KL, Zaharia V, et al,. Up-regulation of extracellular matrix proteoglycans and collagen type I in human crescentic glomerulonephritis. Kidney Int 2001; 59: 532-542. (Pubitemid 32157918)
69. Whiting CV, Tarlton JF, Bailey M, et al,. Abnormal mucosal extracellular matrix deposition is associated with increased TGF-beta receptor-expressing mesenchymal cells in a mouse model of colitis. J Histochem Cytochem 2003; 51: 1177-1189. (Pubitemid 37059529)
70. Crabb RA, Chau EP, Decoteau DM, et al,. Microstructural characteristics of extracellular matrix produced by stromal fibroblasts. Ann Biomed Eng 2006; 34: 1615-1627.
71. Akhmetshina A, Dees C, Pileckyte M, et al,. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008; 58: 2553-2564.
72. Zwetsloot KA, Nedergaard A, Gilpin LT, et al,. Differences in transcriptional patterns of extracellular matrix, inflammatory, and myogenic regulatory genes in myofibroblasts, fibroblasts, and muscle precursor cells isolated from old male rat skeletal muscle using a novel cell isolation procedure. Biogerontology 2012; 13: 383-398.
73. Volk SW, Wang Y, Mauldin EA, et al,. Diminished type III collagen promotes myofibroblast differentiation and increases scar deposition in cutaneous wound healing. Cells Tissues Organs 2011; 194: 25-37.
74. Schürch W, Lagacé R, Seemayer TA,. Myofibroblastic stromal reaction in retracted scirrhous carcinoma of the breast. Surg Gynecol Obstet 1982; 154: 351-358. (Pubitemid 12191246)
75. Lagace R, Grimaud JA, Schurch W, et al,. Myofibroblastic stromal reaction in carcinoma of the breast: variations of collagenous matrix and structural glycoproteins. Virchows Arch A Pathol Anat Histopathol 1985; 408: 49-59. (Pubitemid 16192011)
76. Barsky SH, Rao CN, Grotendorst GR, et al,. Increased content of type V collagen in desmoplasia of human breast carcinoma. Am J Pathol 1982; 108: 276-283. (Pubitemid 12033155)
77. Wilkes DS, Heidler KM, Yasufuku K, et al,. Cell-mediated immunity to collagen V in lung transplant recipients: correlation with collagen V release into BAL fluid. J Heart Lung Transplant 2001; 20: 167.
78. Mares DC, Heidler KM, Smith GN, et al,. Type V collagen modulates alloantigen-induced pathology and immunology in the lung. Am J Respir Cell Mol Biol 2000; 23: 62-70. (Pubitemid 30597096)
79. Betz P, Nerlich A, Wilske J, et al,. Immunohistochemical localization of collagen types I and VI in human skin wounds. Int J Legal Med 1993; 106: 31-34. (Pubitemid 23251711)
80. Mollnau H, Munkel B, Schaper J,. Collagen VI in the extracellular matrix of normal and failing human myocardium. Herz 1995; 20: 89-94.
81. Sabatelli P, Gualandi F, Gara SK, et al,. Expression of collagen VI alpha5 and alpha6 chains in human muscle and in Duchenne muscular dystrophy-related muscle fibrosis. Matrix Biol 2012; 31: 187-196.
82. Specks U, Nerlich A, Colby TV, et al,. Increased expression of type VI collagen in lung fibrosis. Am J Respir Crit Care Med 1995; 151: 1956-1964.
83. Zeichen J, van Griensven M, Albers I, et al,. Immunohistochemical localization of collagen VI in arthrofibrosis. Arch Orthop Trauma Surg 1999; 119: 315-318. (Pubitemid 29408405)
84. Streuli CH, Schmidhauser C, Kobrin M, et al,. Extracellular matrix regulates expression of the TGF-beta 1 gene. J Cell Biol 1993; 120: 253-260. (Pubitemid 23014085)
85. White ES, Baralle FE, Muro AF,. New insights into form and function of fibronectin splice variants. J Pathol 2008; 216: 1-14.
86. Hynes RO,. Fibronectins. Springer-Verlag: New York, 1990.
87. Muro AF, Iaconcig A, Baralle FE,. Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exonic enhancer element and the 5' splicing site. FEBS Lett 1998; 437: 137-141. (Pubitemid 28498256)
88. Borsi L, Castellani P, Risso AM, et al,. Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett 1990; 261: 175-178. (Pubitemid 20064800)
89. Serini G, Bochaton-Piallat ML, Ropraz P, et al,. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 1998; 142: 873-881. (Pubitemid 28381502)
90. Kohan M, Muro AF, White ES, et al,. EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J 2010; 24: 4503-4512.
91. Fontana L, Chen Y, Prijatelj P, et al,. Fibronectin is required for integrin alphavbeta6-mediated activation of latent TGF-beta complexes containing LTBP-1. FASEB J 2005; 19: 1798-1808. (Pubitemid 41598764)
92. Wijelath ES, Rahman S, Namekata M, et al,. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 2006; 99: 853-860. (Pubitemid 44556384)
93. Huang G, Zhang Y, Kim B, et al,. Fibronectin binds and enhances the activity of bone morphogenetic protein 1. J Biol Chem 2009; 284: 25879-25888.
94. Rahman S, Patel Y, Murray J, et al,. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. BMC Cell Biol 2005; 6: 8.
95. Bossard C, Van den Berghe L, Laurell H, et al,. Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide. Cancer Res 2004; 64: 7507-7512. (Pubitemid 39372095)
96. Smith EM, Mitsi M, Nugent MA, et al,. PDGF-A interactions with fibronectin reveal a critical role for heparan sulfate in directed cell migration during Xenopus gastrulation. Proc Natl Acad Sci U S A 2009; 106: 21683-21688.
97. Baldock C, Oberhauser AF, Ma L, et al,. Shape of tropoelastin, the highly extensible protein that controls human tissue elasticity. Proc Natl Acad Sci U S A 2011; 108: 4322-4327.
98. Uitto J, Christiano AM, Kahari VM, et al,. Molecular biology and pathology of human elastin. Biochem Soc Trans 1991; 19: 824-829.
99. Swee MH, Parks WC, Pierce RA,. Developmental regulation of elastin production. Expression of tropoelastin pre-mRNA persists after down-regulation of steady-state mRNA levels. J Biol Chem 1995; 270: 14899-14906.
100. Caves JM, Cui W, Wen J, et al,. Elastin-like protein matrix reinforced with collagen microfibers for soft tissue repair. Biomaterials 2011; 32: 5371-5379.
101. Lamme EN, de Vries HJ, van Veen H, et al,. Extracellular matrix characterization during healing of full-thickness wounds treated with a collagen/elastin dermal substitute shows improved skin regeneration in pigs. J Histochem Cytochem 1996; 44: 1311-1322. (Pubitemid 26376356)
102. 2. Biomaterials 2010; 31: 1655-1665.
103. Venkataraman L, Ramamurthi A,. Induced elastic matrix deposition within three-dimensional collagen scaffolds. Tissue Eng Part A 2011; 17: 2879-2889.
104. Dong XR, Majesky MW,. Restoring elastin with microRNA-29. Arterioscler Thromb Vasc Biol 2012; 32: 548-551.
105. Rosenbloom J, Bashir M, Yeh H, et al,. Regulation of elastin gene expression. Ann N Y Acad Sci 1991; 624: 116-136.
106. Pierce RA, Moore CH, Arikan MC,. Positive transcriptional regulatory element located within exon 1 of elastin gene. Am J Physiol Lung Cell Mol Physiol 2006; 291: L391-L399. (Pubitemid 44343715)
107. Shifren A, Woods JC, Rosenbluth DB, et al,. Upregulation of elastin expression in constrictive bronchiolitis obliterans. Int J Chron Obstruct Pulmon Dis 2007; 2: 593-598.
108. Wagenseil JE, Mecham RP,. New insights into elastic fiber assembly. Birth Defects Res C Embryo Today 2007; 81: 229-240. (Pubitemid 351186172)
109. Ramirez F, Rifkin DB,. Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling. Curr Opin Cell Biol 2009; 21: 616-622.
110. Ramirez F, Sakai LY,. Biogenesis and function of fibrillin assemblies. Cell Tissue Res 2010; 339: 71-82.
111. Ramirez F, Dietz HC,. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev 2007; 17: 252-258. (Pubitemid 46843550)
112. Fleischmajer R, Jacobs L, Schwartz E, et al,. Extracellular microfibrils are increased in localized and systemic scleroderma skin. Lab Invest 1991; 64: 791-798.
113. Godfrey M,. Congenital contractural arachnodactyly. In GeneReviews™ [Internet], Pagon RA, Bird TD, Dolan CR, et al. (eds). University of Washington, Seattle: Seattle, WA; 1993.
114. Avvedimento EV, Gabrielli A,. Stiff and tight skin: a rear window into fibrosis without inflammation. Sci Transl Med 2010; 2: 23ps13.
115. Barisic-Dujmovic T, Boban I, Adams DJ, et al,. Marfan-like skeletal phenotype in the tight skin (Tsk) mouse. Calcif Tissue Int 2007; 81: 305-315. (Pubitemid 47498102)
116. Mangasser-Stephan K, Gartung C, Lahme B, et al,. Expression of isoforms and splice variants of the latent transforming growth factor beta binding protein (LTBP) in cultured human liver myofibroblasts. Liver 2001; 21: 105-113. (Pubitemid 32409537)
117. Zilberberg L, Todorovic V, Dabovic B, et al,. Specificity of latent TGF-ss binding protein (LTBP) incorporation into matrix: role of fibrillins and fibronectin. J Cell Physiol 2012; 227: 3828-3836.
118. Dallas SL, Sivakumar P, Jones CJ, et al,. Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J Biol Chem 2005; 280: 18871-18880. (Pubitemid 41379589)
119. Annes JP, Munger JS, Rifkin DB,. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116: 217-224. (Pubitemid 36163863)
120. Desmoulière A, Geinoz A, Gabbiani F, et al,. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122: 103-111. (Pubitemid 23188802)
121. Serini G, Gabbiani G,. Modulation of alpha-smooth muscle actin expression in fibroblasts by transforming growth factor-beta isoforms: an in vivo and in vitro study. Wound Rep Reg 1996; 4: 278-287. (Pubitemid 126674098)
122. Shah M, Foreman DM, Ferguson MW,. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108: 985-1002.
123. Yoshinaga K, Obata H, Jurukovski V, et al,. Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors. Proc Natl Acad Sci U S A 2008; 105: 18758-18763.
124. Hynes RO,. The extracellular matrix: not just pretty fibrils. Science 2009; 326: 1216-1219.
125. Todorovic V, Rifkin DB,. LTBPs, more than just an escort service. J Cell Biochem 2012; 113: 410-418.
126. Jenkins G,. The role of proteases in transforming growth factor-beta activation. Int J Biochem Cell Biol 2008; 40: 1068-1078.
127. Wipff PJ, Hinz B,. Integrins and the activation of latent transforming growth factor beta1-an intimate relationship. Eur J Cell Biol 2008; 87: 601-615.
128. Bradshaw AD,. The role of SPARC in extracellular matrix assembly. J Cell Commun Signal 2009; 3: 239-246.
129. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al,. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998; 93: 1159-1170. (Pubitemid 28307421)
130. Frangogiannis NG,. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012; 92: 635-688.
131. Grotendorst GR, Duncan MR,. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J 2005; 19: 729-738. (Pubitemid 40617377)
132. Harris BS, Zhang Y, Card L, et al,. SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. Am J Physiol Heart Circ Physiol 2011; 301: H841-H847.
133. Kos K, Wilding JP,. SPARC: a key player in the pathologies associated with obesity and diabetes. Nature Rev Endocrinol 2010; 6: 225-235.
134. Lenga Y, Koh A, Perera AS, et al,. Osteopontin expression is required for myofibroblast differentiation. Circ Res 2008; 102: 319-327. (Pubitemid 351271652)
135. McCurdy S, Baicu CF, Heymans S, et al,. Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). J Mol Cell Cardiol 2010; 48: 544-549.
136. McCurdy SM, Dai Q, Zhang J, et al,. SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 2011; 301: H497-H505.
137. Mori R, Shaw TJ, Martin P,. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 2008; 205: 43-51. (Pubitemid 351185714)
138. Rentz TJ, Poobalarahi F, Bornstein P, et al,. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem 2007; 282: 22062-22071. (Pubitemid 47195756)
139. Singh M, Foster CR, Dalal S, et al,. Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI. J Mol Cell Cardiol 2010; 48: 538-543.
140. Sweetwyne MT, Murphy-Ullrich JE,. Thrombospondin1 in tissue repair and fibrosis: TGF-β-dependent and independent mechanisms. Matrix Biol 2012; 31: 178-186.
141. Borkham-Kamphorst E, van Roeyen CR, Van de Leur E, et al,. CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC. J Cell Commun Signal 2012; 6: 11-25.
142. Colston JT, de la Rosa SD, Koehler M, et al,. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. Am J Physiol Heart Circ Physiol 2007; 293: H1839 - H1846. (Pubitemid 47367233)
143. Heise RL, Stober V, Cheluvaraju C, et al,. Mechanical stretch induces epithelial-mesenchymal transition in alveolar epithelia via hyaluronan activation of innate immunity. J Biol Chem 2011; 286: 17435-17444.
144. Brigstock DR, Goldschmeding R, Katsube KI, et al,. Proposal for a unified CCN nomenclature. Mol Pathol 2003; 56: 127-128. (Pubitemid 36461474)
145. Jun JI, Lau LF,. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nature Rev Drug Discov 2011; 10: 945-963.
146. Chen XM, Qi W, Pollock CA,. CTGF and chronic kidney fibrosis. Frontiers Biosci 2009; 1: 132-141.
147. Gressner OA, Gressner AM,. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008; 28: 1065-1079.
148. Shi-Wen X, Leask A, Abraham D,. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008; 19: 133-144. (Pubitemid 351382279)
149. Fonseca C, Lindahl GE, Ponticos M, et al,. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007; 357: 1210-1220. (Pubitemid 47443180)
150. Shi-wen X, Kennedy L, Renzoni EA, et al,. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007; 56: 4189-4194. (Pubitemid 350262347)
151. Brigstock DR,. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J Cell Commun Signal 2010; 4: 1-4.
152. Wang Q, Usinger W, Nichols B, et al,. Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair 2011; 4: 4.
153. Yates CC, Bodnar R, Wells A,. Matrix control of scarring. Cell Mol Life Sci 2011; 68: 1871-1881.
154. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, et al,. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005; 167: 71-80. (Pubitemid 40884771)
155. Chiquet-Ehrismann R, Chiquet M,. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003; 200: 488-499. (Pubitemid 36818249)
156. Carey WA, Taylor GD, Dean WB, et al,. Tenascin-C deficiency attenuates TGF-ss-mediated fibrosis following murine lung injury. Am J Physiol Lung Cell Mol Physiol 2010; 299: L785-L793.
157. El-Karef A, Yoshida T, Gabazza EC, et al,. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol 2007; 211: 86-94. (Pubitemid 46092033)
158. Mao JR, Taylor G, Dean WB, et al,. Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nature Genet 2002; 30: 421-425.
159. Burch GH, Gong Y, Liu W, et al,. Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nature Genet 1997; 17: 104-108. (Pubitemid 27377542)
160. Egging D, van Vlijmen-Willems I, van Tongeren T, et al,. Wound healing in tenascin-X deficient mice suggests that tenascin-X is involved in matrix maturation rather than matrix deposition. Connect Tissue Res 2007; 48: 93-98. (Pubitemid 46680961)
161. Chen Q, Sivakumar P, Barley C, et al,. Potential role for heparan sulfate proteoglycans in regulation of transforming growth factor-beta (TGF-beta) by modulating assembly of latent TGF-beta-binding protein-1. J Biol Chem 2007; 282: 26418-26430. (Pubitemid 47443781)
162. Gressner OA, Weiskirchen R, Gressner AM,. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 2007; 11: 1031-1051. (Pubitemid 350037048)
163. Webber J, Jenkins RH, Meran S, et al,. Modulation of TGFbeta1-dependent myofibroblast differentiation by hyaluronan. Am J Pathol 2009; 175: 148-160.
164. Simpson RM, Meran S, Thomas D, et al,. Age-related changes in pericellular hyaluronan organization leads to impaired dermal fibroblast to myofibroblast differentiation. Am J Pathol 2009; 175: 1915-1928.
165. Ito T, Williams JD, Fraser D, et al,. Hyaluronan attenuates transforming growth factor-beta1-mediated signaling in renal proximal tubular epithelial cells. Am J Pathol 2004; 164: 1979-1988. (Pubitemid 38669347)
166. Twarock S, Tammi MI, Savani RC, et al,. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells. J Biol Chem 2010; 285: 23274-23282.
167. Hinz B, Dugina V, Ballestrem C, et al,. Alpha-smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts. Mol Biol Cell 2003; 14: 2508-2519. (Pubitemid 36724338)
168. Acharya PS, Majumdar S, Jacob M, et al,. Fibroblast migration is mediated by CD44-dependent TGF beta activation. J Cell Sci 2008; 121: 1393-1402. (Pubitemid 351936304)
169. Li Y, Jiang D, Liang J, et al,. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med 2011; 208: 1459-1471.
170. Frangogiannis NG,. Syndecan-1: a critical mediator in cardiac fibrosis. Hypertension 2010; 55: 233-235.
171. Bartlett AH, Hayashida K, Park PW,. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells 2007; 24: 153-166. (Pubitemid 350177174)
172. Kliment CR, Oury TD,. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med 2010; 49: 707-717.
173. Kliment CR, Englert JM, Gochuico BR, et al,. Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis. J Biol Chem 2009; 284: 3537-3545.
174. Fitzgerald ML, Wang ZH, Park PW, et al,. Shedding of syndecan-1 and-4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000; 148: 811-824.
175. Stepp MA, Daley WP, Bernstein AM, et al,. Syndecan-1 regulates cell migration and fibronectin fibril assembly. Exp Cell Res 2010; 316: 2322-2339.
176. Chen L, Klass C, Woods A,. Syndecan-2 regulates transforming growth factor-beta signaling. J Biol Chem 2004; 279: 15715-15718. (Pubitemid 38509254)
177. Matsui Y, Ikesue M, Danzaki K, et al,. Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ Res 2011; 108: 1328-1339.
178. Jiang D, Liang J, Campanella GS, et al,. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. J Clin Invest 2010; 120: 2049-2057.
179. Kalamajski S, Oldberg A,. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol 2010; 29: 248-253.
180. Hildebrand A, Romaris M, Rasmussen LM, et al,. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994; 302: 527-534. (Pubitemid 24280108)
181. Iozzo RV, Schaefer L,. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 2010; 277: 3864-3875.
182. Honardoust D, Varkey M, Hori K, et al,. Small leucine-rich proteoglycans, decorin and fibromodulin, are reduced in postburn hypertrophic scar. Wound Repair Regen 2011; 19: 368-378.
183. Yamaguchi Y, Mann DM, Ruoslahti E,. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990; 346: 281-284.
184. Melchior-Becker A, Dai G, Ding Z, et al,. Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype. J Biol Chem 2011; 286: 17365-17375.
185. Funderburgh JL, Caterson B, Conrad GW,. Distribution of proteoglycans antigenically related to corneal keratan sulfate proteoglycan. J Biol Chem 1987; 262: 11634-11640.
186. Liu F, Mih JD, Shea BS, et al,. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 2010; 190: 693-706.
187. Grenard P, Bates MK, Aeschlimann D,. Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem 2001; 276: 33066-33078.
188. Lorand L, Graham RM,. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nature Rev Mol Cell Biol 2003; 4: 140-156. (Pubitemid 36172696)
189. Aeschlimann D, Paulsson M,. Transglutaminases: protein cross-linking enzymes in tissues and body fluids. Thromb Haemost 1994; 71: 402-415. (Pubitemid 24100662)
190. Esposito C, Caputo I. Mammalian transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance. FEBS J 2005; 272: 615-631.
191. Gundemir S, Colak G, Tucholski J, et al,. Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys Acta 2012; 1823: 406-419.
192. Nurminskaya MV, Belkin AM,. Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol 2012; 294: 1-97.
193. Wang Z, Griffin M,. TG2, a novel extracellular protein with multiple functions. Amino Acids 2012; 42: 939-949.
194. Huang L, Haylor JL, Hau Z, et al,. Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int 2009; 76: 383-394.
195. Kagan HM,. Lysyl oxidase: mechanism, regulation and relationship to liver fibrosis. Pathol Res Pract 1994; 190: 910-919. (Pubitemid 24370102)
196. Smith-Mungo LI, Kagan HM,. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 1998; 16: 387-398. (Pubitemid 28069865)
197. Kagan HM,. Intra- and extracellular enzymes of collagen biosynthesis as biological and chemical targets in the control of fibrosis. Acta Trop 2000; 77: 147-152.
198. Lopez B, Gonzalez A, Hermida N, et al,. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol 2010; 299: H1-H9.
199. Roy R, Polgar P, Wang Y, et al,. Regulation of lysyl oxidase and cyclooxygenase expression in human lung fibroblasts: interactions among TGF-beta, IL-1 beta, and prostaglandin E. J Cell Biochem 1996; 62: 411-417. (Pubitemid 26301540)
200. Voloshenyuk TG, Landesman ES, Khoutorova E, et al,. Induction of cardiac fibroblast lysyl oxidase by TGF-beta1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine 2011; 55: 90-97.
201. Goto Y, Uchio-Yamada K, Anan S, et al,. Transforming growth factor-beta1 mediated up-regulation of lysyl oxidase in the kidneys of hereditary nephrotic mouse with chronic renal fibrosis. Virchows Arch 2005; 447: 859-868. (Pubitemid 41728876)
202. Chanoki M, Ishii M, Kobayashi H, et al,. Increased expression of lysyl oxidase in skin with scleroderma. Br J Dermatol 1995; 133: 710-715.
203. Di Donato A, Ghiggeri GM, Di Duca M, et al,. Lysyl oxidase expression and collagen cross-linking during chronic adriamycin nephropathy. Nephron 1997; 76: 192-200. (Pubitemid 27254647)
204. Counts DF, Evans JN, Dipetrillo TA, et al,. Collagen lysyl oxidase activity in the lung increases during bleomycin-induced lung fibrosis. J Pharmacol Exp Ther 1981; 219: 675-678. (Pubitemid 12248826)
205. Lopez B, Querejeta R, Gonzalez A, et al,. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension 2012; 60: 677-683.
206. Noblesse E, Cenizo V, Bouez C, et al,. Lysyl oxidase-like and lysyl oxidase are present in the dermis and epidermis of a skin equivalent and in human skin and are associated to elastic fibers. J Invest Dermatol 2004; 122: 621-630. (Pubitemid 38471327)
207. Barker HE, Chang J, Cox TR, et al,. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res 2011; 71: 1561-1572.
208. Vadasz Z, Kessler O, Akiri G, et al,. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol 2005; 43: 499-507. (Pubitemid 41111433)
209. Verzijl N, DeGroot J, Thorpe SR, et al,. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000; 275: 39027-39031. (Pubitemid 32058915)
210. Sivan SS, Wachtel E, Tsitron E, et al,. Collagen turnover in normal and degenerate human intervertebral discs as determined by the racemization of aspartic acid. J Biol Chem 2008; 283: 8796-8801.
211. van Heerebeek L, Hamdani N, Handoko ML, et al,. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117: 43-51. (Pubitemid 350291180)
212. Singh BK, Mascarenhas DD,. Bioactive peptides control receptor for advanced glycated end product-induced elevation of kidney insulin receptor substrate 2 and reduce albuminuria in diabetic mice. Am J Nephrol 2008; 28: 890-899.
213. Tang M, Zhang W, Lin H, et al,. High glucose promotes the production of collagen types I and III by cardiac fibroblasts through a pathway dependent on extracellular-signal-regulated kinase 1/2. Mol Cell Biochem 2007; 301: 109-114. (Pubitemid 46895150)
214. Tokudome T, Horio T, Yoshihara F, et al,. Direct effects of high glucose and insulin on protein synthesis in cultured cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts. Metabolism 2004; 53: 710-715. (Pubitemid 38880899)
215. Martin P, Leibovich SJ,. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 2005; 15: 599-607. (Pubitemid 41619424)
216. Chung AC, Zhang H, Kong YZ, et al,. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol 2010; 21: 249-260.
217. Schnider SL, Kohn RR,. Glucosylation of human collagen in aging and diabetes mellitus. J Clin Invest 1980; 66: 1179-1181. (Pubitemid 11233822)
218. Booth AJ, Hadley R, Cornett AM, et al,. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Resp Crit Care Med 2012; doi 10.1164/rccm.201204-0754OC.
219. Kornblihtt AR, Pesce CG, Alonso CR, et al,. The fibronectin gene as a model for splicing and transcription studies. FASEB J 1996; 10: 248-257. (Pubitemid 26079944)
220. Muro AF, Chauhan AK, Gajovic S, et al,. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. Journal Cell Biol 2003; 162: 149-160. (Pubitemid 36859542)
221. Muro AF, Moretti FA, Moore BB, et al,. An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 638-645. (Pubitemid 351442171)
222. Rodriguez HM, Vaysberg M, Mikels A, et al,. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor. J Biol Chem 2010; 285: 20964-20974.
223. Barry-Hamilton V, Spangler R, Marshall D, et al,. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nature Med 2010; 16: 1009-1017.
224. Cox TR, Erler JT,. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 2011; 4: 165-178.
225. Lugassy J, Zaffryar-Eilot S, Soueid S, et al,. The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation. J Biol Chem 2012; 287: 3541-3549.
226. Gullberg D,. Shift happens-a paradigm shift for the role of integrins in fibrosis. Matrix Biol 2009; 28: 383.
227. Kim KK, Wei Y, Szekeres C, et al,. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest 2009; 119: 213-224.
228. Carracedo S, Lu N, Popova SN, et al,. The fibroblast integrin alpha11beta1 is induced in a mechanosensitive manner involving activin A and regulates myofibroblast differentiation. J Biol Chem 2010; 285: 10434-10445.
229. Talior-Volodarsky I, Connelly KA, Arora PD, et al,. α11 integrin stimulates myofibroblast differentiation in diabetic cardiomyopathy. Cardiovasc Res 2012; doi 10.1093/cvr/cvs259.
230. Hinz B,. Masters and servants of the force: the role of matrix adhesions in myofibroblast force perception and transmission. Eur J Cell Biol 2006; 85: 175-181.
231. Chan MW, Chaudary F, Lee W, et al,. Force-induced myofibroblast differentiation through collagen receptors is dependent on mammalian diaphanous (mDia). J Biol Chem 2010; 285: 9273-9281.
232. Horan GS, Wood S, Ona V, et al,. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008; 177: 56-65.